All | Synchronous | Metachronous | p | |
---|---|---|---|---|
Total no. of patients | 75 | 39 | 36 | |
Age, years | ||||
mean ± SD | 59.1 ± 8,4 | 59.5 ± 9,1 | 58.5 ± 7,6 | 0.63b |
range | 39-77 | 39-77 | 42-77 | |
Sex, no. (%) | ||||
Male | 43 (57) | 23 (59) | 20 (56) | 0.76c |
Female | 32 (43) | 16 (41) | 16 (44) | |
KPS, no. (%) | ||||
70 | 9 (12) | 3 (8) | 6 (17) | |
80 | 38 (51) | 14 (36) | 24 (66) | 0.002d |
90 | 28 (37) | 22 (56) | 6 (17) | |
Weight loss, no. (%) | ||||
<5% | 65 (87) | 36 (92) | 29 (81) | 0.18e |
>5% | 10 (13) | 3 (8) | 7 (19) | |
Histology | ||||
Adenocarcinoma | 50 (67) | 26 (67) | 24 (66) | |
Squamous | 17 (23) | 9 (23) | 8 (22) | 1.0d |
Other | 8 (10) | 4 (10) | 4 (11) | |
T-Stagea, no. (%) | ||||
T1 | 11 (15) | 3 (8) | 8 (22) | |
T2 | 37 (50) | 21 (54) | 17 (47) | 0.36c |
T3 | 12 (16) | 7 (18) | 5 (14) | |
T4 | 14 (19) | 8 (20) | 6 (17) | |
N-Stagea, no. (%) | ||||
N0 | 28 (38) | 10 (25) | 19 (53) | |
N1 | 14 (19) | 7 (18) | 7 (19) | 0.06d |
N2 | 28 (38) | 19 (49) | 9 (25) | |
N3 | 4 (5) | 3 (8) | 1 (3) | |
Thoracic UICC stage, no. (%) | ||||
IA | 4 (5) | 1 (3) | 3 (8) | |
IB | 7 (9) | 4 (10) | 3 (8) | |
IIA | 14 (19) | 6 (15) | 9 (25) | 0.08d |
IIB | 10 (14) | 2 (5) | 8 (22) | |
IIIA | 25 (34) | 17 (44) | 8 (22) | |
IIIB | 14 (19) | 9 (23) | 5 (14) | |
Localization of metastases, no. (%) | ||||
Brain | 51 (62) | 26 (59) | 25 (65) | |
Bone | 7 (8) | 5 (11) | 2 (5) | |
Lung | 9 (11) | 5 (11) | 4 (11) | |
Lymphatic | 5 (6) | 4 (9) | 1 (3) | 0.16d |
Adrenal Gland | 3 (4) | 3 (7) | 0 | |
Soft tissue | 3 (4) | 0 | 3 (8) | |
Other | 4 (5) | 1 (2) | 3 (8) | |
No. of metastases, no. (%) | ||||
1 | 57 (76) | 29 (74) | 28 (78) | |
2 | 11 (15) | 6 (15) | 5 (14) | 1.0d |
3–5 | 7 (10) | 4 (10) | 3 (8) | |
No. of involved organs, no. (%) | ||||
1 | 68 (91) | 34 (87) | 34 (95) | 0.43e |
> 2 | 7 (9) | 5 (13) | 2 (5) | |
Treatment of primary tumor, no. (%) | ||||
Surgery ± (neo)adjuvant RT and/or CT | 55 (73) | 26 (66) | 29 (80) | |
RCT | 18 (24) | 12 (31) | 6 (17) | 0.34d |
SBRT | 2 (3) | 1 (3) | 1 (3) | |
Treatment of oligometastases, no. (%) | ||||
Surgery | 12 (14) | 7 (16) | 5 (13) | |
SRS/hSRT/SBRT | 19 (23) | 10 (22) | 9 (23) | 0.88d |
Surgery/RT combined | 49 (58) | 25 (56) | 24 (61) | |
cf-RT | 4 (5) | 3 (7) | 1 (3) | |
FDG-PET based staging, no. (%) | 51 (68) | 34 (87) | 17 (47) | |
Additional chemotherapy, no. (%) | 48 (64) | 27 (69) | 21 (58) | |
FEV1, % predicted | ||||
mean ± SD | 76 ± 24 | 77 ± 27 | 74 ± 20 | 0.20b |